<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医麦客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2020-11-21T11:16:23+08:00</updated>
  <subtitle>医麦客是一个聚焦转化医学、精准医疗和生物制药的专业媒体平台，持续关注体外诊断、抗体药物、细胞治疗、基因治疗等细分领域。为新生物医药医疗领域的企业发声，推动企业和行业的快速发展。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>在体改造CAR-T细胞大幅降低成本！新贵生物技术公司完成5300万美元A轮融资丨医麦黑科技</title>
    <updated>2020-11-20T23:31:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/6IFuiW7IjpSoxLSXzeAITg</id>
    <link href="https://mp.weixin.qq.com/s/6IFuiW7IjpSoxLSXzeAITg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>第三款RNAi药物上市！Alnylam坐拥RNAi领域江山丨医麦猛爆料</title>
    <updated>2020-11-20T23:31:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/b3Y-VIv23OzFoTXG4MRnRw</id>
    <link href="https://mp.weixin.qq.com/s/b3Y-VIv23OzFoTXG4MRnRw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>​马军教授：免疫靶向治疗方兴未艾，联合治疗是未来发展方向</title>
    <updated>2020-11-20T23:31:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/KYWtcNl6Zrp6myntHV9zbg</id>
    <link href="https://mp.weixin.qq.com/s/KYWtcNl6Zrp6myntHV9zbg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」君赛生物创始人金华君博士：TIL将成为晚期实体肿瘤非常有前景的治疗方向</title>
    <updated>2020-11-20T23:31:06+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/wsNVuuwu2ndxcHIk2jwflg</id>
    <link href="https://mp.weixin.qq.com/s/wsNVuuwu2ndxcHIk2jwflg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>快速发展的生物制药领域驱动CDMO产能不断扩大，如何全面评估最适合您需求的CDMO合作伙伴？丨星耀研究院</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/tFbAHiYX5Hh9pXCUSIP1Gg</id>
    <link href="https://mp.weixin.qq.com/s/tFbAHiYX5Hh9pXCUSIP1Gg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>全球首推全长Claudin18.2蛋白——抗体药质量放行篇​</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/BLGZA1kzXknCqCsiI-JO7Q</id>
    <link href="https://mp.weixin.qq.com/s/BLGZA1kzXknCqCsiI-JO7Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>mRNA疫苗研发火热进行，行业如何把控安全性及免疫效力评价的关键环节丨医麦课堂</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/SzVtgSrjv2Dtm5i5Yh4IGg</id>
    <link href="https://mp.weixin.qq.com/s/SzVtgSrjv2Dtm5i5Yh4IGg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>95%超高有效率！复星新冠疫苗国内如何桥接加快上市？丨医麦新观察</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/psPpUNMlUirm3pDbVL4BZQ</id>
    <link href="https://mp.weixin.qq.com/s/psPpUNMlUirm3pDbVL4BZQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>溶瘤病毒新种类，更优的安全性实现静脉给药丨医麦猛爆料</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/4UddUeVJSPOn8SKYGUziUw</id>
    <link href="https://mp.weixin.qq.com/s/4UddUeVJSPOn8SKYGUziUw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>王建祥教授：CAR-NK细胞疗法—治疗血液肿瘤的又一利器</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/2f8GVFLs9ap7kV9vPznd8Q</id>
    <link href="https://mp.weixin.qq.com/s/2f8GVFLs9ap7kV9vPznd8Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>瑞创生物研发的国内第一款异体免疫细胞治疗产品RC1012注射液临床试验获中国国家药监局默示许可丨医麦猛爆料</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/LKys2JIIlsUOaA66gf6xPw</id>
    <link href="https://mp.weixin.qq.com/s/LKys2JIIlsUOaA66gf6xPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」纽安津董事长陈枢青：新生抗原治疗肿瘤一定是正确方向</title>
    <updated>2020-11-20T09:19:37+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-20:/s/IQW6t9rBC0O_K8SLzZ8EiA</id>
    <link href="https://mp.weixin.qq.com/s/IQW6t9rBC0O_K8SLzZ8EiA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>药融资丨国投招商领投CAR-T头部企业，合源生物完成4.5亿元新一轮融资，自主知识产权CAR-T产品进入临床II期</title>
    <updated>2020-11-18T22:44:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/dpqacvCPoM0-LhGJkmdobw</id>
    <link href="https://mp.weixin.qq.com/s/dpqacvCPoM0-LhGJkmdobw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>生物医药供应链国产品牌的产业化之路丨医麦新观察</title>
    <updated>2020-11-18T22:44:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/ndN6ranhMwT9C4sphUi4Rg</id>
    <link href="https://mp.weixin.qq.com/s/ndN6ranhMwT9C4sphUi4Rg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>mRNA疫苗研发系列公开课第一场精彩回顾 | 医麦新观察</title>
    <updated>2020-11-18T22:44:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/VoScbJD4yQt5d_yKANIrcQ</id>
    <link href="https://mp.weixin.qq.com/s/VoScbJD4yQt5d_yKANIrcQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>生物医药企业如何从容应对人类遗传资源监管及最新注册法规？</title>
    <updated>2020-11-18T22:44:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/_vCFOBCIEtSJT1UGnOjuKg</id>
    <link href="https://mp.weixin.qq.com/s/_vCFOBCIEtSJT1UGnOjuKg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>周剑峰教授：进一步优化CAR-T疗法向终极治疗方向发展，更好地融合于现有治疗体系</title>
    <updated>2020-11-18T22:44:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/gOnyDa6jRsn2-d0uLeBNCw</id>
    <link href="https://mp.weixin.qq.com/s/gOnyDa6jRsn2-d0uLeBNCw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>「峰客访谈」中盛溯源联合创始人张颖：推动中国iPSC来源细胞药物研发达到发达国家同等水平</title>
    <updated>2020-11-18T22:44:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/PrxTj1lJkPjZpah1fW1S2A</id>
    <link href="https://mp.weixin.qq.com/s/PrxTj1lJkPjZpah1fW1S2A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>利用人工智能的力量快速设计寡核苷酸药物，BioMarin与AI新贵公司达成合作丨医麦猛爆料</title>
    <updated>2020-11-18T22:44:21+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/_QWE2-jEMCNBt1erdYhfhQ</id>
    <link href="https://mp.weixin.qq.com/s/_QWE2-jEMCNBt1erdYhfhQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>1000万美元IND里程碑付款，礼来和Dicerna合作的RNAi疗法将启动心脏代谢性疾病的临床研究丨医麦猛爆料</title>
    <updated>2020-11-18T13:26:59+08:00</updated>
    <id>tag:mp.weixin.qq.com,2020-11-18:/s/vL4u_Pc2WxD8mbd-viS-nw</id>
    <link href="https://mp.weixin.qq.com/s/vL4u_Pc2WxD8mbd-viS-nw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>